Abstract
Introduction:Alzheimer’s disease and vascular dementia are the two most common types of dementia, with significant overlap of clinical symptoms and pathology. Previous results from a 6-month, double-blind, placebo-controlled, international, multicentre study of the cholinomimetic galantamine in patients with probable vascular dementia or mixed dementia (Alzheimer’s disease with cerebrovascular disease) showed significant cognitive, behavioural and functional benefits in these patients. Furthermore, results of a 6-month, open-label extension of this study confirmed that patients with vascular dementia or Alzheimer’s disease with cerebrovascular disease may benefit from galantamine therapy for at least 1 year. The objective of the current analysis was to determine if the long-term cognitive benefits of galantamine seen in the above-mentioned study are influenced by dementia type (probable vascular dementia vs Alzheimer’s disease with cerebrovascular disease).
Study design: A post hoc sub-analysis of a 6-month, multicentre, randomised, double-blind, placebo-controlled study and a subsequent 6-month, open-label extension.
Patients and methods: Patients diagnosed with probable vascular dementia or Alzheimer’s disease with cerebrovascular disease were treated with galantamine (Reminyl®) 24 mg/day for 12 months (6 months double-blind and 6 months open-label) or placebo for 6 months (double-blind) followed by galantamine 24 mg/day for 6 months (open-label). Changes in scores on the 11-item Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-cog/11) were assessed at months 6, 7.5 and 12. Mean changes from baseline were analysed.
Results: Patients with probable vascular dementia treated with galantamine for 6 or 12 months showed significant improvements in ADAS-cog/11 scores versus baseline, which were maintained at the end of the 12-month study. Patients who had Alzheimer’s disease with cerebrovascular disease continuously treated with galantamine maintained the cognitive abilities seen at baseline for at least 12 months. Additionally, patients who had Alzheimer’s disease with cerebrovascular disease who were switched from placebo to open-label galantamine therapy for 6 months demonstrated cognitive benefits, but these benefits were significantly less than those observed in patients treated with galantamine continuously for the 12-month period.
Galantamine was well tolerated throughout the entire 12-month study.
Conclusions: These findings suggest that the drug is efficacious for such common forms of dementia as vascular dementia and Alzheimer’s disease with cerebrovascular disease. Moreover, some patients benefit from galantamine therapy that is initiated early, soon after diagnosis, and continued for at least 1 year.
Similar content being viewed by others
Notes
The use of tradenames is for product identification purposes only and does not imply endorsement
References
Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465–79
Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 1999; 12: 35–48
Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000; 54: S4–9
Pendlebury WW, Solomon PR. Alzheimer’s disease. Clin Symp 1996; 48: 2–32
Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14: 240–57
Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment: Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54: 447–51
Kalaria RN. The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging 2000; 21: 321–30
Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13Suppl. 3: SI 15–23
Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813–36
Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997; 277: 813–7
Pasquier F, Leys D, Scheltens P. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer’s disease. J Neural Transm Suppl 1998; 54: 117–27
Saito H, Togashi H, Yoshioka M, et al. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 1: S257–9
Kimura S, Saito H, Minami M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167–78
Togashi H, Kimura S, Matsumoto M, et al. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996; 27: 520–5
Togashi H, Matsumoto M, Yoshioka M, et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117–20
Ferrari R, Frasoldati A, Leo G, et al. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci Lett 1999; 277: 169–72
Gottfries CG, Blennow K, Karlsson I, et al. The neurochemistry of vascular dementia. Dementia 1994; 5: 163–7
Wallin A, Alafuzoff I, Carlsson A, et al. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 1989; 79: 397–406
Tohgi H, Abe T, Kimura M, et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211–20
Davis KL, Powchik P. Tacrine. Lancet 1995; 345: 625–30
Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 2001; 49: 279–88
Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurol Scand Suppl 2000; 176: 68–73
Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002; 203-204: 141–6
Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159–69
Meyer JS, Chowdhury MH, Xu G, et al. Donepezil treatment of vascular dementia. Ann N Y Acad Sci 2002; 977: 482–6
Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999; 11: 268–70
Erkinjuntti T, Kurz A, Gauthier S, etal. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–90
Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64
Schneider LS, Olin JT, Doody RS, etal. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11Suppl. 2: S22–32
Feldman H, Sauter A, Donald A, et al. The Disability Assessment for Dementia Scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15: 89–95
Cummings JL. The Neuropsychiatrie Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48Suppl. 6: S10–6
Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003; 25: 1765–82
Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized mini-mental state examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry 1991; 148: 102–5
Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci 2002; 203-204: 57–65
Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002; 977: 513–22
Torfs K. 12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer’s disease: two randomized, placebo-controlled studies [abstract]. Neurobiol Aging 2000; 21(1 Suppl.): S242–3
Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76
Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445–9
Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–95
Acknowledgements
Publication of this article was made possible through an unrestricted education grant from Janssen Pharmaceutica Products, L.P.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Small, G., Erkinjuntti, T., Kurz, A. et al. Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease. CNS Drugs 17, 905–914 (2003). https://doi.org/10.2165/00023210-200317120-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200317120-00004